Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 2:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 131 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Oxycodone Clear all
Completed Early Phase 1 Interventional

Trial Comparing a Multi-Modal Pain Protocol With and Without Opioids Following Total Joint Arthroplasty

NCT03845881
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
Oxycodone, Placebo Oral Tablet
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 89 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Oct 17, 2026, 2:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Intranasal Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-103)

NCT05567354
View directory record Official record
Conditions
Recreational Drug Use
Interventions
PF614, Oxycodone, Placebo
Drug · Other
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 17, 2026, 2:09 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Abuse Potential of HORIZANT With and Without Oxycodone in Healthy, Nondependent Recreational Opioid Users

NCT06247488
View directory record Official record
Conditions
Abuse Potential
Interventions
Placebo, Oxycodone 20 mg, GE-IR 200 mg, GE-IR 450 mg
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 17, 2026, 2:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Abuse Potential of Intranasal Cebranopadol

NCT06453265
View directory record Official record
Conditions
Abuse, Drug
Interventions
Cebranopadol- 600 ug, Cebranopadol- 800ug, Cebranopadol- 1000ug, Treatment A:, Treatment B, Treatment C, Qualification
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 17, 2026, 2:09 PM EDT
Completed Phase 3 Interventional

A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Acute Pain and Opioid-Induced Nausea and Vomiting (OINV)

NCT02462811
View directory record Official record
Conditions
Pain, Nausea, Vomiting
Interventions
CL-108 (hydrocodone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg), Placebo, Norco (hyrdocodone 7,5 mg, acetaminophen 325 mg)
Drug
Lead sponsor
Joseph Hazelton
Industry
Eligibility
18 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Oct 17, 2026, 2:09 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-104)

NCT05571345
View directory record Official record
Conditions
Recreational Drug Use
Interventions
PF614, Oxycodone Hydrochloride 40 mg, Placebo
Drug
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 17, 2026, 2:09 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study Evaluating the Abuse Potential of NEURONTIN® in Healthy Non-drug Dependent, Recreational Opioid Users

NCT05319756
View directory record Official record
Conditions
Abuse Potential
Interventions
gabapentin 600 mg, gabapentin 1200 mg, gabapentin 600 mg and oxycodone HCl 20 mg, gabapentin 1200 mg and oxycodone HCl 20 mg, oxycodone HCl 20 mg, placebo
Drug
Lead sponsor
Viatris Specialty LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 17, 2026, 2:09 PM EDT
Completed Phase 4 Interventional Results available

Hormone Function in Men Treated for Pain With Opioids or Placebo

NCT00737737
View directory record Official record
Conditions
Chronic Pain, Osteoarthritis
Interventions
MS Contin, Placebo
Drug
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
30 Years to 65 Years · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Oct 17, 2026, 2:09 PM EDT
Terminated Phase 3 Interventional Results available

Ibuprofen to Decrease Opioid Use and Post-operative Pain Following Unilateral Inguinal Herniorrhaphy

NCT02929589
View directory record Official record
Conditions
Pain, Hernia
Interventions
Ibuprofen, Opioid Medication, Placebo, Ibuprofen + Opioid medication
Drug
Lead sponsor
Mike O'Callaghan Military Hospital
Federal
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Nellis Air Force Base, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 17, 2026, 2:09 PM EDT
Recruiting Phase 1Phase 2 Interventional

Opioid Drug Interaction Study

NCT06757140
View directory record Official record
Conditions
Drug Interactions, Drug Kinetics
Interventions
Alprazolam, Oxycodone, Placebo
Drug
Lead sponsor
Shanna Babalonis, PhD
Other
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 17, 2026, 2:09 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists.

NCT03389750
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Intravenous Challenge Drug
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Lexington, Kentucky • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 17, 2026, 2:09 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Abuse Potential of Gabapentin Taken Orally Concomitantly With Oxycodone Hydrochloride in Healthy, Non-Drug-Dependent, Recreational Opioid Users

NCT07813026
View directory record Official record
Conditions
Healthy
Interventions
Placebo, Oxycodone 20mg, gabapentin 600 mg, Gabapentin 1200mg, Gabapentin 600 mg + Oxycodone 20 mg, Gabapentin 1200 mg + Oxycodone 20 mg
Drug
Lead sponsor
Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 17, 2026, 2:09 PM EDT
Completed Phase 4 Interventional Results available

A Randomized Study of Three Medication Regimens for Acute Low Back Pain

NCT01587274
View directory record Official record
Conditions
Acute Low Back Pain
Interventions
Naproxen, Cyclobenzaprine, Oxycodone/ acetaminophen
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years to 64 Years
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 17, 2026, 2:09 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Dextromethorphan as a Novel Non-opioid Adjunctive Agent for Pain Control in Medication Abortion

NCT03480009
View directory record Official record
Conditions
Abortion in First Trimester
Interventions
Dextromethorphan Hydrobromide, Avicel PH101 (Microcrystalline Cellulose NF) for Compounding, Oxycodone
Drug
Lead sponsor
Study Investigator-Sponsor
Other
Eligibility
18 Years and older · Female only
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 17, 2026, 2:09 PM EDT
Completed Phase 4 Interventional Results available

Opioid Treatment for Chronic Low Back Pain and the Impact of Mood Symptoms

NCT01502644
View directory record Official record
Conditions
Chronic Low Back Pain, Degenerative Disc Disease, Depression, Anxiety
Interventions
Oxycodone, Morphine, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 17, 2026, 2:09 PM EDT
Terminated Phase 2 Interventional Results available

Relieving Acute Pain (RAP) Study: A Pilot Study

NCT03426137
View directory record Official record
Conditions
Trauma, Opioid Use, Spine Fusion
Interventions
Oxycodone, Ketorolac, Placebo
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 17, 2026, 2:09 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.

NCT00613938
View directory record Official record
Conditions
Arthralgia, Bunion, Hallux Valgus, Pain
Interventions
Tapentadol (CG5503), oxycodone, placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 80 Years
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
7
States / cities
Glendale, California • Pasadena, Maryland • Austin, Texas + 4 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 17, 2026, 2:09 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users

NCT01030406
View directory record Official record
Conditions
Opioid Abuse
Interventions
40/0mg taken first, 80/0mg taken first, 40/240mg taken first, 80/480mg taken first, 0/0mg taken first
Drug
Lead sponsor
Acura Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Oct 17, 2026, 2:09 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of IV Acetaminophen for Pain Management

NCT02028715
View directory record Official record
Conditions
Post-operative Pain
Interventions
Placebo, IV acetaminophen
Drug
Lead sponsor
Aultman Health Foundation
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 17, 2026, 2:09 PM EDT
Completed Phase 3 Interventional

The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.

NCT00315848
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal delivery system
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1999
U.S. locations
10
States / cities
Huntsville, Alabama • Phoenix, Arizona • Westminster, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated May 3, 2006 · Synced Oct 17, 2026, 2:09 PM EDT
Terminated Phase 4 Interventional Results available

Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis

NCT00414453
View directory record Official record
Conditions
Neuropathic Pain, Chronic Pain, Multiple Sclerosis
Interventions
Lidocaine patch 5%, Extended-release oxycodone, Placebo extended-release oxycodone pills, Placebo lidocaine patches
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2015 · Synced Oct 17, 2026, 2:09 PM EDT
Active, not recruiting Phase 2 Interventional

Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid Exposure

NCT05463367
View directory record Official record
Conditions
Opioid Use, Opioid Dependence, Opioid-use Disorder, Narcotic Use, Back Pain, Back Injuries, Chronic Pain, Chronic Low-back Pain, Pain, Chronic, Pain;Back Low;Chronic, Pain, Back
Interventions
Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet, Naproxen 500 Mg, Opioids
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 17, 2026, 2:09 PM EDT
Recruiting Phase 3 Interventional

PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301)

NCT06602271
View directory record Official record
Conditions
Postoperative Pain, Acute
Interventions
PF614 capsule, Placebo
Drug
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Atlanta, Georgia • Houston, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 17, 2026, 2:09 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Fentanyl Buccal Tablet Use in the Emergency Department for Isolated Extremity Injury

NCT01270659
View directory record Official record
Conditions
Pain
Interventions
Fentanyl, oxycodone/acetaminophen
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 17, 2026, 2:09 PM EDT